TLR7 and neoplasm: Intraperitoneal injection of the TLR7 agonist resiquimod in mice with pancreatic ductal adenocarcinoma (PDAC) tumors reduces Tregs in the TME, enhances activation, infiltration, and cytotoxicity of CD8+ T cells, suppressing tumor growth and improving survival (65).